Pliant Therapeutics, Inc. PLRX
0.79 USD -0.01 (-1.74%)
At closeNov 10, 2026, 4:00 PM EST
0.79 0.00 +0.55%
After hours · Nov 10, 4:00 PM ET
0.77 Day range 0.8187
0.77 52-week range 1.82
- YTD
- -35.60%
- 1 year
- -51.50%
News
globenewswire.com Pliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced the presentation of preclinical proof-of-concept data and new clinical…
globenewswire.com Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of…
globenewswire.com Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA) Recognized leader in RNAi drug discovery with track record of advancing novel delivery platforms and therapeutics to drive Company's integrin-mediated delivery platform
globenewswire.com Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026 Features FORTIFY, the ongoing Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) --…
globenewswire.com Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer Leader in targeted immuno-oncology drug development brings three decades of academic and biopharmaceutical oncology expertise
defenseworld.net Reviewing Pliant Therapeutics (NASDAQ:PLRX) & Black Diamond Therapeutics (NASDAQ:BDTX) Pliant Therapeutics (NASDAQ: PLRX - Get Free Report) and Black Diamond Therapeutics (NASDAQ: BDTX - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will…
defenseworld.net Connor Clark & Lunn Investment Management Ltd. Makes New $611,000 Investment in Pliant Therapeutics, Inc. $PLRX Connor Clark and Lunn Investment Management Ltd. bought a new stake in Pliant Therapeutics, Inc. (NASDAQ: PLRX) in the undefined quarter, according to its most recent filing with the Securities and…
benzinga.com Pliant Therapeutics Receives Fast Track Designation From FDA For PLN-101095 In Combination With Pembrolizumab For Potential Treatment Of Solid Tumors Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced the receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for PLN-101095, an oral, small molecule, dual selective…
globenewswire.com Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors SOUTH SAN FRANCISCO, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced the receipt of Fast Track designation from the U.S. Food and Drug…
benzinga.com Pliant Therapeutics Q2 EPS $(0.36) Misses $(0.34) Estimate Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.34) by 5.88 percent. This is a 49.3 percent increase over losses of…
globenewswire.com Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results FORTIFY, a Phase 1b indication expansion trial of PLN-101095, experiencing strong enrollment Appointed seasoned oncology drug development leaders Flavia Borellini, Ph.D. and Robert Iannone, M.D.
globenewswire.com Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D. Appointments bring global oncology drug development experience and deepen Board's operational and regulatory expertise
seekingalpha.com Pliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript Pliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
globenewswire.com Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant…
globenewswire.com Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095 Oral presentation at AACR 2026 featured updated data from Phase 1 trial of PLN-101095 showing deepening of…
globenewswire.com Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of…
benzinga.com Pliant Therapeutics Announces Dosing Of First Participant In FORTIFY Phase 1b Open-Label Indication Expansion Clinical Trial Of PLN-101095 In Combination With Pembrolizumab, In Patients With ICI-Refractory Advanced Or Metastatic Solid Tumors Pliant Therapeutics (NASDAQ:PLRX) today announced the dosing of the first participant in the FORTIFY Phase 1b open-label indication expansion clinical trial of PLN-101095 in combination with…
globenewswire.com Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics (Nasdaq: PLRX) today announced the dosing of the first participant in the FORTIFY Phase 1b open-label indication…
globenewswire.com Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased to 19 months Data highlighted in oral presentation at AACR's Clinical…
defenseworld.net Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of “Reduce” by Analysts Shares of Pliant Therapeutics, Inc. (NASDAQ: PLRX - Get Free Report) have been assigned an average rating of "Reduce" from the five brokerages that are currently covering the company, Marketbeat.com…
defenseworld.net Head-To-Head Review: Pliant Therapeutics (NASDAQ:PLRX) versus Dermata Therapeutics (NASDAQ:DRMA) Dermata Therapeutics (NASDAQ: DRMA - Get Free Report) and Pliant Therapeutics (NASDAQ: PLRX - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast…- benzinga.com Pliant Therapeutics Presents Data From Phase 1 Trial Of PLN-101095 At AACR Annual Meeting 2026 Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the presentation of data from…
globenewswire.com Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of…- benzinga.com Canaccord Genuity Maintains Hold on Pliant Therapeutics, Lowers Price Target to $3 Canaccord Genuity analyst Edward Nash maintains Pliant Therapeutics (NASDAQ:PLRX) with a Hold and lowers the price target from $4 to $3.
benzinga.com Piper Sandler Maintains Overweight on Pliant Therapeutics, Lowers Price Target to $3 Piper Sandler analyst Yasmeen Rahimi maintains Pliant Therapeutics (NASDAQ:PLRX) with a Overweight and lowers the price target from $4 to $3.
benzinga.com Pliant Therapeutics Q4 EPS $(0.38) Beats $(0.41) Estimate Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.41) by 7.77 percent. This is a 53.66 percent increase over losses of…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
benzinga.com Nasdaq Surges 1%; ON Semiconductor Shares Plunge Following Earnings Miss 
benzinga.com Tesla, ON Semiconductor And Other Big Stocks Moving Lower In Monday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
benzinga.com Why BP Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket - benzinga.com Why RH Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
benzinga.com Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session Shares of Air Products and Chemicals, Inc. (NYSE: APD) fell sharply during Monday’s session after the company reported worse-than-expected first-quarter financial results and lowered FY24 adjusted…- benzinga.com Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in today’s session.
benzinga.com Stocks That Hit 52-Week Lows On Thursday During the session on Thursday, 461 stocks hit new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Friday Friday's session saw 169 companies set new 52-week lows.
- benzinga.com Why First Republic Bank Shares Are Trading Lower By 34%; Here Are 20 Stocks Moving Premarket Gainers Hongli Group Inc. (NASDAQ: HLP) gained 317.8% to $17.55 in pre-market trading. Hongli Group recently announced pricing of $8.25 million initial public offering of 2,062,500 ordinary shares at…
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
- benzinga.com Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday Gainers
benzinga.com Why Adamis Pharmaceuticals Is Trading Lower By Around 44%, Here Are 46 Stocks Moving In Wednesday's Mid-Day Session Gainers- benzinga.com Alibaba, Zoom Video And 76 Biggest Movers From Yesterday Gainers Kaspien Holdings Inc. (NASDAQ: KSPN) shares climbed 161.9% to close at $6.81 on Monday on heavy volume amid mention of the stock on social media.
- benzinga.com Why These Casino Stocks Are Moving Lower, Here's 45 Stocks Moving In Monday's Mid-Day Session Gainers Pliant Therapeutics, Inc. (NASDAQ: PLRX) jumped 112.6% to $18.88 after the company said its treatment for Idiopathic Pulmonary Fibrosis was well tolerated in a Phase 2a study.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 807 companies reached new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday, 849 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 242 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's session, 454 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 671 companies achieved new lows for the year.